Results 1 to 10 of about 695,872 (210)

Thymic carcinoma [PDF]

open access: yesApplied Radiology, 2016
Thymic carcinomas are a heterogeneous group of aggressive, invasive epithelial malignancies. Their incidence is rare, occurring predominantly in middle-aged men. Here we present the typical imaging findings of a thymic carcinoma. The combination of imaging characteristics with tumor location and patient age provides a roadmap for approaching the ...
Costas Stavrakis   +3 more
core   +12 more sources

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report

open access: yesCase Reports in Oncology, 2013
Thymic carcinoma is a rare but aggressive neoplasm. Although there is no clearly optimal first- or second-line chemotherapy regimen for thymic carcinoma, platinum-based chemotherapy has repeatedly been shown to be of benefit to patients with advanced ...
Satoshi Igawa   +7 more
doaj   +2 more sources

Successful Concurrent Chemoradiotherapy with Cisplatin plus Vinorelbine for Locally Advanced Thymic Carcinoma

open access: yesCase Reports in Oncology, 2014
Little information is available about the usefulness of concurrent chemoradiotherapy for locally advanced thymic carcinoma due to a rare anterior mediastinal tumor.
Toshirou Fukushima   +5 more
doaj   +2 more sources

Hepatoid thymic carcinoma: a case report of a rare subtype of thymic carcinoma [PDF]

open access: yesJournal of Pathology and Translational Medicine, 2021
Hepatoid thymic carcinoma is an extremely rare subtype of primary thymus tumor resembling "pure" hepatoid adenocarcinomas with hepatocyte paraffin 1 (Hep-Par-1) expression. A 53-year-old man presented with voice change and a neck mass. Multiple masses involving the thyroid, cervical and mediastinal lymph nodes, and lung were detected on computed ...
Ji-Seon Jeong   +5 more
openaire   +4 more sources

Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report

open access: yesFrontiers in Immunology, 2022
Thymic carcinoma is a rare and aggressive disease with poor outcome. There is no established treatment regimen for advanced thymic carcinoma. While the efficacy of pembrolizumab was proved to be promising, as a single agent, in patients with refractory ...
Cui Chen, Peng Sun, Jianting Long
doaj   +1 more source

Thymic carcinoma metastasize to the small intestine: a case report

open access: yesBMC Gastroenterology, 2020
Background Thymic carcinoma is a rare mediastinal neoplasm with a high malignant potential. It often shows pleural invasion and distant metastasis. The metastasis of thymic carcinoma to the small intestine is rarely reported and difficult to distinguish ...
Yi Yuan   +4 more
doaj   +1 more source

De novo thymic carcinoma or malignant transformation: a myasthenic patient presented with multiple mediastinal tumours

open access: yesRespirology Case Reports, 2020
A 63‐year‐old man presented with bilateral ptosis, and detailed evaluation confirmed ocular myasthenia gravis with three anterior mediastinal masses on computed tomography (CT) of the chest.
Chu‐Pin Pai   +4 more
doaj   +1 more source

Quantitative texture analysis based on dynamic contrast enhanced MRI for differential diagnosis between primary thymic lymphoma from thymic carcinoma

open access: yesScientific Reports, 2022
To evaluate the value of texture analysis based on dynamic contrast enhanced MRI (DCE-MRI) in the differential diagnosis of thymic carcinoma and thymic lymphoma. Sixty-nine patients with pathologically confirmed (thymic carcinoma, n = 32; thymic lymphoma,
Jia-jia Zhu   +6 more
doaj   +1 more source

Total thymectomy for thymic lymphoepithelioma-like carcinoma—report of two cases

open access: yesSurgical Case Reports, 2019
Background Thymic carcinoma has been classified into 12 subtypes, thymic lymphoepithelioma-like carcinoma (LELC) is a type of them, and has a pathological organization similar to that of lymphoepithelioma, an undifferentiated type of nasopharyngeal ...
Sachi Kawagishi   +8 more
doaj   +1 more source

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma

open access: yesThoracic Cancer, 2023
Background Thymic squamous cell carcinoma and type B3 thymoma are primary neoplasms of the anterior mediastinum that are sometimes difficult to differentiate from one another histologically.
Koichiro Kanamori   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy